Stoke Therapeutics (STOK) Q1 2026 earnings review
Clinical Validation and Capital Fortification
For a clinical-stage biotech, earnings are about two things: pipeline execution and cash runway. Stoke delivered on both fronts in Q1 2026. Zorevunersen's new 4-year data demonstrated sustained cognitive and behavioral improvements, proving it as a potential disease-modifying therapy rather than just a seizure suppressant. To bridge the gap to the mid-2027 Phase 3 readout, management opportunistically tapped its ATM facility for $80.7M, reversing a trend of declining cash balances and extending the runway into 2028. While Q1 revenue plummeted 96% YoY to $6.2M (entirely expected, as last year included a $150.8M Biogen IP license recognition) and OPEX accelerated, the de-risked balance sheet keeps the bull thesis intact.
🐂 Bull Case
Four-year open-label extension (OLE) data showed statistically significant cognitive and behavioral improvements. This differentiates zorevunersen from standard anti-seizure medicines and vastly improves its ultimate commercial profile.
With $411M in cash on hand, Stoke is funded through the mid-2027 EMPEROR Phase 3 readout and into early 2028 launch readiness, removing near-term financing overhangs.
🐻 Bear Case
Elevated cerebrospinal fluid (CSF) protein remains a notable side effect, presenting in 94% of patients and classified as a treatment-emergent adverse event in 59% of cases.
Operating expenses jumped 26% YoY to $59.6M. The $80.7M ATM capital raise came at the cost of 2.6 million new shares, diluting existing shareholders ahead of major catalysts.
⚖️ Verdict: 🟢
Bullish. Stoke successfully exchanged moderate equity dilution for total balance sheet security ahead of its Phase 3 readout. The long-term clinical data is compelling enough to justify the accelerating commercial readiness spend.
Key Themes
TANGO RNA Platform Yields Cognitive Benefits
Stoke's proprietary TANGO approach (Targeted Augmentation of Nuclear Gene Output) is showing true disease-modifying potential. The latest 4-year longitudinal data proved that restoring NaV1.1 protein expression doesn't just reduce seizures—it drove statistically significant improvements in cognition and behavior across 1, 2, 3, and 4 years. This is a massive clinical differentiator.
EMPEROR Study Enrollment Near Finish Line
The Phase 3 EMPEROR study is progressing at a stable, highly predictable clip. New patient screening in the U.S., UK, and Japan is now closed, with 130 patients already randomized out of the ~150 target. The final patient is expected to be randomized in June 2026, perfectly securing the timeline for a mid-2027 readout.
Data Contradiction: 'Well-Tolerated' vs CSF Protein Spikes
Management repeatedly characterizes zorevunersen as 'generally well tolerated,' but the data shows elevated CSF protein lab values occurred in 94% of patients, with 59% classified as a treatment-emergent adverse event (TEAE). While the company emphasizes that there have been no severe clinical manifestations or hydrocephalus, a 94% incidence rate is a glaring anomaly that will draw intense FDA safety scrutiny.
Navigating the Macro Funding Environment
In a volatile macro environment where pre-commercial biotechs face steep capital costs, Stoke chose to utilize its ATM facility aggressively in Q1, selling 2.6 million shares to raise $80.7M. While this smartly fortifies the balance sheet, it represents an accelerating trend of shareholder dilution required to support the increasing commercialization spend.
Pipeline Expansion: Beyond Dravet
Stoke is quietly derisking its broader pipeline. STK-002 for Autosomal Dominant Optic Atrophy (ADOA) dosed its first patient in the Phase 1 OSPREY study in February 2026, with dose escalation planned through early 2027. Concurrently, lead optimization is underway for a SYNGAP1 clinical candidate. This proves Stoke is not entirely a single-asset company.
Other KPIs
Accelerating. Combined OPEX grew 26% YoY (from $47.3M in 25Q1). R&D expenses rose to $39.7M to support zorevunersen advancement, while SG&A jumped 36% to $20.0M driven by an explicit shift toward launch readiness.
Reversing. Revenue plummeted from $158.6M in 25Q1. This drop is entirely structural and expected, as the prior year included a massive $150.8M one-time IP license performance recognition tied to the Biogen agreement. Normalized revenue is stable.
Reversing. The company swung from a net income of $112.9M ($1.90/share) in 25Q1 back to a net loss of $50.0M (-$0.79/share), driven by the absence of the upfront Biogen milestone and the rising R&D/SG&A spend.
Guidance
Stable. The $411.0M in cash, cash equivalents, and marketable securities safely bridges the company past the mid-2027 Phase 3 readout and covers the anticipated early 2028 U.S. launch window.
Stable. The company confirmed it is on track to complete randomization of approximately 150 patients across the U.S., UK, and Japan by June 2026.
Stable. The timeline for the ultimate commercial catalyst—the EMPEROR study data readout—remains locked for mid-2027.
Accelerating process. Stoke plans to begin submitting modules for the New Drug Application in Q1 2027, well before the final Phase 3 data is available, utilizing its Breakthrough Therapy Designation to expedite regulatory pathways.
Key Questions
Rolling NDA Strategy
You plan to initiate the rolling NDA in Q1 2027, prior to the Phase 3 readout in mid-2027. Which specific modules are prioritized for early submission, and what feedback has the FDA provided on this timeline?
CSF Protein Monitoring
Given that 94% of patients in the OLE studies exhibited elevated CSF protein, what specific safety monitoring protocols are mandated in the EMPEROR study, and do you anticipate black box warnings or strict REMS requirements upon potential approval?
Commercial Spend Trajectory
SG&A increased by over $5M this quarter due to launch readiness. With a potential launch still almost two years away, what is the expected quarterly trajectory for SG&A spend through 2026?
ATM Utilization Strategy
After utilizing the ATM for $80.7M this quarter, what is your framework for further capital raises before the mid-2027 data readout? Are you targeting a specific minimum cash balance leading into the NDA filing?